Top

Published in:

01-07-2011 | Short Communication

Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients

Authors: François Glowacki, Arnaud Lionet, Jean-Philippe Hammelin, Myriam Labalette, François Provôt, Marc Hazzan, Franck Broly, Christian Noël, Dr Christelle Cauffiez

Published in: Clinical Pharmacokinetics | Issue 7/2011

Abstract

Background and Objective: Tacrolimus is metabolized by cytochrome P450 (CYP) 3A5. The objective of this study was to investigate the influence of the genetic polymorphism of CYP3A5 on the pharmacokinetics of a new modified-release, once-daily formulation of tacrolimus (Advagraf®) after a switch from the immediate-release formulation (Prograf®)

Patients and Methods: This was a prospective, single-centre, open-label study in stable kidney transplant recipients. Seventeen ‘expressor’ patients (CYP3A5*1/*3 or *1/*1) were matched to 15 ‘non-expressor’ patients (CYP3A5*3/*3). Exposure variables (concentrations and area under the blood concentration-time curve from 0 to 24 hours [AUC₂₄]) were obtained before and 15 days after the switch. Delay since grafting was similar for both groups of patients (expressors: 49±24 months; non-expressors: 45±22 months).

Results: During administration of tacrolimus as Prograf® or Advagraf®, the mean tacrolimus daily dose was significantly higher and the dose-adjusted AUC₂₄ was significantly lower in the expressor group. Following the switch to Advagraf®, there was a significant decrease in the dose-adjusted AUC₂₄ for both non-expressor (5910 ± 3019 vs 5334 ± 2668 ng · h/mL per mg/kg/day; p = 0.041) and expressor patients (3701 ± 1409 vs 3273 ± 1372 ng · h/mL per mg/kg/day; p = 0.03). In the non-expressor group, mean blood trough concentration (C₀) was comparable for both formulations while it decreased significantly in the expressor group after the switch (8.2 ± 2.2 vs 6.3 ± 2.5ng/mL; p = 0.02). However, a good correlation between AUC₂₄ and C₀ was observed for both Advagraf® and Prograf® regardless of CYP3A5 genotype.

Conclusion: Tacrolimus exposure significantly decreases after a switch from Prograf® to Advagraf®, on a milligram-for-milligram basis, in CYP3A5 expressor recipients. Consequently, these patients should be carefully monitored.

Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007 Jul; 8(7): 835–49PubMedCrossRef

Jose M. Caring for Australians with Renal Impairment (CARI). The CARI guidelines: calcineurin inhibitors in renal transplantation. Adverse effects. Nephrology (Carlton) 2007 Feb; 12 Suppl. 1: S66–74CrossRef

Coates PT. Caring for Australians with Renal Impairment (CARI). The CARI guidelines: nephrotoxicity and calcineurin inhibitors. Nephrology (Carlton) 2007 Feb; 12 Suppl. 1: S85–7CrossRef

Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004 Oct; 78(8): 1182–7PubMedCrossRef

Haufroid V, Wallemacq P, Van Kerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant 2006 Nov;6(11): 2706–13PubMedCrossRef

Wlodarczyk Z, Squifflet JP, Ostrowski M, et al. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9: 2505–13PubMedCrossRef

Benkali K, Rostaing L, Premaud A, et al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 2010 Oct; 49(10): 683–92PubMedCrossRef

de Jonge H, Kuypers DR, Verbeke K, et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010 Sep; 90(5): 523–9PubMedCrossRef

Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5* 1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011 Apr; 21(4): 179–84PubMed

10.

Wallemacq P, Goffinet JS, O’Morchoe S, et al. Multi-site analytical evaluation of the Abbott Architect tacrolimus assay. Ther Drug Monit 2009 Apr; 31(2): 198–204PubMedCrossRef

11.

Thervet E, Loriot AM, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010 Jun; 87(6): 721–6PubMed

12.

Haufroid V, Mourad M, van Kerckhove V, et al. The effects of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004 Mar; 14(3): 147–54PubMedCrossRef

13.

MacPhee IAM, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics; the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in Whites and South Asians. Transplantation 2005 Feb; 79(4): 499–502PubMedCrossRef

14.

Hesselink DA, van Schaik RHN, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008 Apr; 18(4): 339–48PubMedCrossRef

15.

Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010 Mar; 49(3): 141–75PubMedCrossRef

16.

Alloway R, Steinberg S, Khalil K, et al. Conversion of stable kidney transplant recipients from a twice daily Prograf®-based regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005 Mar; 37(2): 867–70PubMedCrossRef

17.

Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit 2010 Apr; 32(2): 129–35PubMed

18.

Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European Consensus Conference. Ther Drug Monit 2009 Apr; 31(2): 139–52PubMedCrossRef

19.

Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation 2008; 5 Suppl. 7: S19–24CrossRef

20.

Thervet E, Anglicheau D, Legendre C, et al. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther Drug Monit 2008 Apr; 30(2): 143–50PubMedCrossRef

21.

Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993 Mar; 268 (9): 6077–80PubMed

22.

Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010 Apr; 49(4): 207–21PubMedCrossRef

23.

Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997 Sep; 27(2-3): 201–14PubMedCrossRef

24.

Wang D, Johnson A, Papp A, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005 Oct; 15(10): 693–704PubMedCrossRef

25.

Opden Buijsch RAM, Christiaans MHL, Stolk LML, et al. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007 Aug; 21(4): 427–35CrossRef

26.

Naesens M, Lerut E, de Jonge H, et al. Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009 Nov; 20(11): 2468–80PubMedCrossRef

Title: Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients
Authors: François Glowacki
Arnaud Lionet
Jean-Philippe Hammelin
Myriam Labalette
François Provôt
Marc Hazzan
Franck Broly
Christian Noël
Dr Christelle Cauffiez
Publication date: 01-07-2011
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 7/2011
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/11587050-000000000-00000

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2011

Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia?

Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders

Asenapine Pharmacokinetics in Hepatic and Renal Impairment

Lidocaine (Lignocaine) Dosing Regimen Based upon a Population Pharmacokinetic Model for Preterm and Term Neonates with Seizures